Glioblastoma Doctors Abroad — Page 3

Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at Liv Hospital Topkapı. He specializes in treating colon, breast, gastric, and lung cancers. He previously served as the Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital. Dr. Atci is a member of the American Society of Clinical Oncology (ASCO).

• Author of 19 peer-reviewed papers on gastrointestinal, thoracic, and endocrine cancers.
• Published studies on survival outcomes for stage IIB colon cancer in the Journal of Chemotherapy.
• Researches prognostic biomarkers using PET/CT scans and metabolic tumor volume.
• Treats complex oncological cases at the university-affiliated İstinye University clinic.

Dr. Irfan Cicin is a Professor of Medical Oncology at İstinye University Liv Hospital Topkapı. He specializes in treating complex cancers, including glioblastoma, lung cancer, and pancreatic tumors. He serves as a professor at the Trakya University Faculty of Medicine. Dr. Cicin previously served as a physician in the Turkish Air Force.

• Performs systemic therapies such as immunotherapy, chemotherapy, and hormone therapy.
• Treats a wide range of conditions including gynecologic, orthopedic, and neuro-oncology cases.
• Expert in HIPEC and chemoembolization for liver and abdominal malignancies.
• Works at a 300-bed university hospital with 33 medical departments.

Dr. Alemdar specializes in Medical Oncology with extensive training from Akdeniz University, focusing on personalized treatment plans.

• Completed Medical Oncology residency at Akdeniz University
• Over 20 years of experience in oncology and internal medicine
• Works at Medical Park Antalya Hospital Complex
• Experienced in academic and clinical settings

Dr. Mariam Abu Zeid is a clinical oncologist at Shefaa Al Orman International Oncology Hospitals. She is certified by the European Society for Medical Oncology. Dr. Abu Zeid treats solid tumors and hematologic cancers. She holds a Ph.D. in Clinical Oncology and Nuclear Medicine from Ain Shams University.

• Administers chemotherapy, immunotherapy, and targeted treatments for various cancer types.
• Oversees oncology clinical trials and manages treatment-related toxicities.
• Coordinates patient care within multidisciplinary teams for complex staging and diagnosis.
• Practices at an ESMO-accredited center that treats approximately 6,000 patients annually.

Professor Zheng Qiu Hong is Director of the Cell Therapy Research Center and a National Senior Expert in Biotherapy. He is a Professor and Master’s Supervisor at Fujian Medical University. He has more than 30 years of clinical experience in tumor molecular biology and biotherapy. From 2012 to 2013, he was a visiting scholar in stem cell research at the University of Connecticut School of Life Sciences. He previously held leadership roles at Fujian Cancer Hospital. These roles included Director of the Tumor Molecular Biology Laboratory and Director of the Surgical Oncology Research Laboratory. He also served as Deputy Director of the Fujian Key Laboratory of Tumor Biotherapy and Deputy Director of the Biotherapy and Immunotherapy Center.

Appointments include Standing Committee Member of the Biotherapy Committee of the Chinese Research Hospital Association. He is also a Committee Member of the Tumor Immunology and Biotherapy Committee of the Chinese Society for Immunology. In addition, he is Deputy Chair of the Academic Committee of the Xiamen Cell Therapy Research Center at the First Affiliated Hospital of Xiamen University.

Dr. Raanan Berger is the Director of the Cancer Center at Sheba Medical Center. He was listed in Forbes Israel’s “Best Doctors” in 2025. Dr. Berger specializes in genitourinary oncology and radiates complex prostate tumors. He completed a postdoctoral fellowship at the Dana-Farber/Harvard Cancer Institute.

• Heads the clinical research unit focusing on molecular oncology.
• Co-authored over 20 peer-reviewed papers on prostate cancer and BRCA mutations.
• Member of the American Society of Clinical Oncology (ASCO).
• Performs systemic therapy and radiotherapy at a Top-10 globally ranked hospital.

Dr. Yaacov Lawrence is the Chair of Radiation Oncology at Sheba Medical Center. He specializes in precision radiation therapy and neuro-oncology. Dr. Lawrence pioneered celiac plexus radiosurgery for pancreatic cancer pain management. He holds the FASTRO designation, one of the highest honors in his specialty.

• Leads the Gastrointestinal Cancer Program at Sheba Medical Center.
• Performs stereotactic radiosurgery for brain tumors and nervous system cancers.
• Authored over 280 scientific publications on personalized radiation protocols.
• Completed radiation oncology fellowship training at Thomas Jefferson University.

Dr. Mohamed Mahmoud Abdelhakim is a Professor of Radiation Oncology at Cairo University’s National Cancer Institute. He serves as the Head of Radiation Oncology at Shefa al Orman Hospital. Dr. Abdelhakim treats complex cancers, including breast, soft tissue sarcoma, and gynecologic tumors. He is a member of ESTRO and ESMO.

• Performs image-guided brachytherapy and stereotactic radiotherapy.
• Uses IMRT, VMAT, SRS, and SBRT for precise tumor targeting.
• Provides total body and total skin irradiation for bone marrow transplants.
• Practices at ESMO-accredited Shefa al Orman Hospital in Luxor.

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

Dr. Do Hyun Nam is renowned for endoscopic brain surgeries and tumor removal at Samsung Medical Center – one of South Korea's top hospitals.

• Specializes in both pediatric and adult neurosurgery
• Expert in treating benign and malignant brain tumors
• Performs advanced radiosurgery procedures

Dr. Graus led the expert panel that first defined strict diagnostic criteria for paraneoplastic neurological syndromes, a major breakthrough in neuro-oncology.

• MD and PhD from Universitat Autonoma de Barcelona
• Neuro-Oncology fellowship at Memorial Sloan-Kettering Cancer Center
• Founder and past president of European Association of Neuro-Oncology
• Emeritus investigator at IDIBAPS research institute
• Former chief of neurology at Hospital Clinic Barcelona

An oncologist who trained at the world-renowned Sloan-Kettering Cancer Center in New York. Dr. Jablonski-Perec applies that deep expertise in her work at Hadassah Medical Center.

• Professor in the Oncology Department at the Hebrew University
• Head of the Breast Cancer Treatment Center since 1998
• Holds a Doctor of Medical Sciences degree
• Member of several international cancer communities
• Awarded a scholarship from the Hadassah Medical School

Prof. Elke Jaeger is one of Germany's top oncologists according to Focus rating. She leads Oncology and Hematology at Nordwest Clinic.

• 41 years of experience in oncology
• Specializes in sarcoma and oncohematology
• Head of Oncology and Hematology department

Among leading neurosurgeons globally, Prof. Akalan performs brain and nerve surgeries using advanced O-arm Imaging and iMRI.

• 38 years of experience in neurosurgery
• Specializes in pediatric epilepsy and glioma cases
• Published 117 scientific papers on neurosurgery
• Uses ultrasound-guided techniques to minimize complications

Director of the Experimental Neurosurgery Unit at San Raffaele, Professor Mortini specializes in minimally invasive brain and spine surgeries.

• Over of neurosurgery experience
• Expert in neuronavigation and neuromapping for precision
• Patented a method for tissue regeneration
• Visiting Professor at George Washington University